Thelansis

Relapsed or Refractory Metastatic Colorectal Cancer Market Outlook Thelansis’s “Relapsed or Refractory Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and pat...

Relapsed or Refractory Metastatic Colorectal Cancer  Market Outlook Thelansis’s “Relapsed or Refractory Metastatic Colorectal Cancer   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Metastatic Colorectal Cancer   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Metastatic Colorectal Cancer   Overview Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to...

  Relapsed or Refractory Metastatic Colorectal Cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

  Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to affect the prognosis of CRC in men adversely. About a quarter of a contributor to genetic predisposition. The development time of CRC usually lasts from several to several years; therefore, it is essential to diagnose it early in developing the disease. Previously diagnosed with cancer, a history of colon polyps, inflammatory bowel diseases, diabetes mellitus, or cholecystectomy may lead to colorectal cancer (CRC). Surgery encompasses the primary form of treatment for colon cancer, whereas chemotherapy is used most commonly in the adjuvant setting. The 5-year overall survival for patients with localized, regional, and metastatic colon cancer is 91%, 72%, and 13%. Clinical outcomes in mCRC have improved significa...